Mission Pharmacal Partners with TriLogic Pharma on Drug Delivery Platform

Technology will be utilized in development of women’s health medication.

SAN ANTONIO--(BUSINESS WIRE)-- Mission Pharmacal Company announced today that it is developing a new drug delivery system utilizing technology developed by TriLogic Pharma. The delivery system will be based upon TriLogic’s proprietary drug delivery platform TRI-726 and will be licensed to Mission Pharmacal for future drug development.

“Mission Pharmacal’s growth over the last 60 years has been the result of good relationships with other innovative pharmaceutical companies. We look forward to working with TriLogic and its new technology,” stated Terry Herring, president of Mission Pharmacal’s Commercial Operations.

Jim Harwick, president of TriLogic Pharma, said, “We are excited to partner with Mission Pharmacal on the development of a new drug delivery system. We continue to be pleased with the versatility of TRI-726 and the wide range of therapeutic classes and actives that can be developed with our novel delivery platform.”

About Mission Pharmacal

Mission Pharmacal is a privately held pharmaceutical company based in San Antonio. For more than 60 years, the company has been committed to meeting the unique healthcare needs of women throughout all stages of life, pediatric patients, and those persons dealing with urologic conditions. The company has a proven track record of identifying unmet healthcare needs and in developing both innovative prescription and over-the-counter products to meet those needs. Mission Pharmacal provides physicians and consumers with the highest quality pharmaceutical and dietary supplement products on the market today. The company uses only the purest and most reliable ingredients in its products. For more information about the company, visit www.missionpharmacal.com.

About TriLogic Pharma

TriLogic Pharma is a specialty pharmaceutical company working on clear solutions for innovative drug delivery. Their proprietary drug delivery platform, TRI-726, is capable of delivering a large number of actives over several hours to several days. The platform focuses on three logics of in-situ gelation, sustained-erosion and bio-resorption, and adhesion. The three logics, when combined, provide ease of use, better tolerability, and therapy compliance. TriLogic Pharma is based in Montgomery, AL. For more information visit www.trilogicpharma.com or call toll free 866-562-8042.



CONTACT:

Media Contact for Mission Pharmacal:
DEETER Strategic Public Relations
Drew Deeter
[email protected]
215-348-3890
or
Media Contact for TriLogic Pharma:
Shannon Leighty
Director of Marketing
417-861-1148
[email protected]

KEYWORDS:   United States  North America  Texas

INDUSTRY KEYWORDS:   Women  Health  Biotechnology  Medical Devices  Pharmaceutical  Consumer

MEDIA:

Logo
 Logo

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.